Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance.

Berridge BR, Schultze AE, Heyen JR, Searfoss GH, Sarazan RD.

ILAR J. 2016 Dec;57(2):120-132. doi: 10.1093/ilar/ilw028.

PMID:
28053066
2.

The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.

Guth BD, Chiang AY, Doyle J, Engwall MJ, Guillon JM, Hoffmann P, Koerner J, Mittelstadt S, Ottinger S, Pierson JB, Pugsley MK, Rossman EI, Walisser J, Sarazan RD.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:70-90. doi: 10.1016/j.vascn.2015.02.002. Epub 2015 Apr 3.

3.

Cardiovascular pressure measurement in safety assessment studies: technology requirements and potential errors.

Sarazan RD.

J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):210-23. doi: 10.1016/j.vascn.2014.06.003. Epub 2014 Jun 14. Review.

PMID:
24933393
4.

A public-private consortium advances cardiac safety evaluation: achievements of the HESI Cardiac Safety Technical Committee.

Pierson JB, Berridge BR, Brooks MB, Dreher K, Koerner J, Schultze AE, Sarazan RD, Valentin JP, Vargas HM, Pettit SD.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):7-12. doi: 10.1016/j.vascn.2013.03.008. Epub 2013 Apr 6.

5.

Left ventricular pressure, contractility and dP/dt(max) in nonclinical drug safety assessment studies.

Sarazan RD, Kroehle JP, Main BW.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):71-8. doi: 10.1016/j.vascn.2012.05.009. Epub 2012 May 31.

PMID:
22659561
6.

Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities.

Sarazan RD, Mittelstadt S, Guth B, Koerner J, Zhang J, Pettit S.

Int J Toxicol. 2011 May;30(3):272-86. doi: 10.1177/1091581811398963. Epub 2011 Apr 28.

PMID:
21527643
7.

Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys.

McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD.

J Pharmacol Toxicol Methods. 2010 Sep-Oct;62(2):127-35. doi: 10.1016/j.vascn.2010.05.018. Epub 2010 Jun 15.

PMID:
20558308
8.

Left thoracotomy surgical approach for chronic instrumentation in dogs and monkeys providing high-quality electrocardiogram signals.

Henriques TA, Beck TW, Douglas CL, Jones HM, Kremer JJ, Kruzich PJ, Sarazan RD.

J Pharmacol Toxicol Methods. 2010 Sep-Oct;62(2):136-42. doi: 10.1016/j.vascn.2010.05.017. Epub 2010 Jun 13.

PMID:
20550968
9.

Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagle dogs.

Mitchell AZ, McMahon C, Beck TW, Sarazan RD.

J Pharmacol Toxicol Methods. 2010 Jul-Aug;62(1):54-63. doi: 10.1016/j.vascn.2010.04.005. Epub 2010 May 8.

PMID:
20435151
10.

Standing on the shoulders of giants: Dean Franklin and his remarkable contributions to physiological measurements in animals.

Sarazan RD, Schweitz KT.

Adv Physiol Educ. 2009 Sep;33(3):144-56. doi: 10.1152/advan.90208.2008. Erratum in: Adv Physiol Educ. 2009 Dec;33(4):233.

11.

A call for more integrated cardiovascular safety assessment.

Pettit SD, Berridge B, Sarazan RD.

J Pharmacol Toxicol Methods. 2010 Jan-Feb;61(1):1-2. doi: 10.1016/j.vascn.2009.08.001. Epub 2009 Aug 23.

PMID:
19706331
12.

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.

Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr.

Pharm Res. 2006 Jun;23(6):1133-43. Epub 2006 May 25.

PMID:
16715368
13.

Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs.

Chiang AY, Smith WC, Main BW, Sarazan RD.

J Pharmacol Toxicol Methods. 2004 Sep-Oct;50(2):121-30.

PMID:
15385086
14.

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 2002 May;301(2):427-34.

PMID:
11961040
15.

Equine coronary hemodynamics during brief coronary occlusions at three levels of collateral function.

Williams DO, Boatwright RB, Rugh KS, Ross CR, Sarazan RD, Garner HE, Griggs DM Jr.

Am J Physiol. 1996 Jun;270(6 Pt 2):H1893-904.

PMID:
8764237
16.
17.

A review of the toxicology of the antibiotic MICOTIL 300.

Jordan WH, Byrd RA, Cochrane RL, Hanasono GK, Hoyt JA, Main BW, Meyerhoff RD, Sarazan RD.

Vet Hum Toxicol. 1993 Apr;35(2):151-8. Review.

PMID:
8470360
18.

Distribution of coronary collateral blood flow at different levels of collateral growth in conscious ponies.

Boatwright RB, Williams DO, Rugh KS, Sarazan RD, Ross CR, Garner HE, Griggs DM Jr.

Am J Physiol. 1992 Oct;263(4 Pt 2):H1145-53.

PMID:
1415763
19.

Disuse inhibition of newly functional coronary collateral circulation in ponies.

Rugh KS, Ross CR, Sarazan RD, Boatwright RB, Williams DO, Garner HE, Griggs DM Jr.

Am J Physiol. 1992 Feb;262(2 Pt 2):H385-90.

PMID:
1539697
20.

Effects of coronary occlusion duration on reactive hyperemia in conscious dogs and ponies.

Sarazan RD, Krause GF, Franklin D, Garner HE, Griggs DM Jr.

Am J Physiol. 1991 Sep;261(3 Pt 2):H768-73.

PMID:
1887924
21.

Cardiovascular effects of detomidine, a new alpha 2-adrenoceptor agonist, in the conscious pony.

Sarazan RD, Starke WA, Krause GF, Garner HE.

J Vet Pharmacol Ther. 1989 Dec;12(4):378-88.

PMID:
2575673

Supplemental Content

Loading ...
Support Center